SCHEMBL25253797

SCHEMBL25253797

O=C(Nc1ccccc1)c1cccc(-c2ccc(/C=C3\Sc4ccccc4C3=O)o2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN5 P54829 2/20 0.61
PTPN1 P18031 1/20 0.61
PTPN7 P35236 1/20 0.61
DUSP3 P51452 1/20 0.61
PTPN22 Q9Y2R2 1/20 0.61
PIK3CG P48736 3/20 0.50
GSK3A P49840 2/20 0.48
GSK3B P49841 2/20 0.48
POLB P06746 5/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
L3MBTL1 Q9Y468 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
PKM P14618 1/20 0.47
PIM1 P11309 2/20 0.46
MAPT P10636 2/20 0.45
APEX1 P27695 1/20 0.45
ALDH1A1 P00352 3/20 0.45
NPC1 O15118 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25253799 1.00 PTPN5 (0.61) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL26168414 0.90 PTPN5 (0.52) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL6721181 0.88 PTPN5 (0.71) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL26168409 0.88 PTPN5 (0.58) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL25213157 0.86 PTPN5 (0.58) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL25267611 0.86 PTPN5 (0.58) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL25214331 0.86 PTPN5 (0.58) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL25266824 0.86 PTPN5 (0.58) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL26168431 0.85 PTPN22 (0.79) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL26168397 0.84 PTPN5 (0.66) PTPN5PTPN1PTPN7DUSP3PTPN22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed
WO-2023091674-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2023-05-25 WO disclosed
WO-2023091674-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2023-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 PTPN5 8/4885PTPN1 3/4885PTPN7 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.